The results further demonstrated that plasma exosomal MUC5B and SELL could serve as potential biomarkers for diagnosing LC patients with BM, and plasma exosomal APOH could be a novel potential diagnostic biomarker for LC patients with LM. This evidence concerns the gene MUC5B and laryngotracheoesophageal cleft.